{"filing":{"accession_number":"0001493152-26-043562","cik":"0000109657","ticker":"GTBP","company_name":"GT Biopharma, Inc.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-18","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226043562/form8-k.htm"},"events":[{"id":33982,"run_id":31283,"accession_number":"0001493152-26-043562","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"GT Biopharma disclosed a private placement of Series M Convertible Preferred Stock and warrants under Item 1.01 and Item 3.02 (Unregistered Sales of Equity Securities). The company issued 8,611.111 shares of preferred stock convertible into common stock, plus warrants equal to 100% of conversion shares, for $7.75 million in aggregate purchase price. This is a classic dilutive equity issuance raising capital through unregistered securities, with additional dilution from the Greenshoe Rights option for up to $31.2 million more. The filing explicitly references Rule 506(b) of Regulation D, confirming the private placement nature.","company_name":"GT Biopharma, Inc.","ticker":"GTBP","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":37588,"accession_number":"0001493152-26-043562","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"GT Biopharma disclosed a private placement of Series M Convertible Preferred Stock and warrants under Item 1.01 and Item 3.02 (Unregistered Sales of Equity Securities). The company issued 8,611.111 shares of preferred stock convertible into common stock, plus warrants equal to 100% of conversion shares, for $7.75 million in aggregate purchase price. This is a classic dilutive equity issuance raising capital through unregistered securities, with additional dilution from the Greenshoe Rights option for up to $31.2 million more. The filing explicitly references Rule 506(b) of Regulation D, confirming the private placement nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:12:44.220007+00:00","company_name":"GT Biopharma, Inc.","ticker":"GTBP","filing_date":"2026-09-21"}]}